Targeted therapies for cancer
US9750741B2 · kind B2 · utility
0Cited by
1References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 17, 2014 |
| Grant date | Sep 5, 2017 |
| Priority date | — |
| Expiry date | May 5, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.